Improving Cancer Imaging and Detection for Better Patient Care

Current methods of imaging employ tracer compounds with limited ability to detect small tumors and cancerous lymph nodes. Associated images fail to provide the surgeon with important information concerning the extent of disease. Enlyton’s ATA series antibodies address this shortcoming. Radiolabeled ATA series antibodies are cancer-specific. They target early and late stage tumors as well as cancerous lymph nodes in PET and PET/CT. Resultant scans more accurately reflect the extent of cancer, thus enabling oncologists and surgeons to better determine the course of therapy and predict the outcome of disease.